Tysabri Approved In EU; Biogen Will Initiate A Staggered Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec/Elan’s natalizumab is indicated for second-line use, mirroring the revised U.S. indication.